NIH Study Defines Features of Rare Disease, Suggests Potential Therapy Autoantibodies—immune system proteins that target and react with a person's own tissues or organs—are prevalent in people with idiopathic CD4 lymphopenia (ICL) and may contribute to disease progression, a NIAID study has found. There are currently no specific therapies for ICL, a rare disease characterized by persistently low numbers of CD4 T cells, which leads to increased risk of severe infections. The new findings, recently published online in the Journal of Clinical Investigation, suggest that therapies that suppress autoantibodies may hold potential for treatment of the condition. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107